Figures & data
Table 1. Demographic and main clinical characteristics at baseline (n = 1208).
Table 2. Proportion of patients experiencing side-effects at the baseline visit (n = 1208).
Table 3. Multivariate model.
Table 4. Utility decrements associated to EPS, weight gain, sedation, and sexual dysfunction in literature.
Morss SE, Lenert LA, Faustman WO. The side effects of antipsychotic drugs and patients’ quality of life: patient education and preference assessment with computers and multimedia. Proc Annu Symp Comput Appl Med Care 1993:17-21 Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment, 1997 Cummins C. SAKS. The use of olanzapine as a first and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee report. Birmingham: Development and Evaluation Service. Department of Public Health and Epidemiology, University of Birmingham, 1998 Lenert LA, Ziegler J, Lee T, et al. Differences in health values among patients, family members, and providers for outcomes in schizophrenia. Med Care 2000;38:1011-21 Lee TT, Ziegler JK, Sommi R, et al. Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. J Psychiatr Res 2000;34:201-10 Oh P, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4:137-56 Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:155-65 Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105 Adrianzen C, Arango-Davila C, Araujo DM, et al. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. Hum Psychopharmacol 2010;25:439-47